The AI Biotech Fund is a specialised, data-driven investment fund combining artificial intelligence and fundamental analysis to uncover mispriced opportunities in the biotech sector. We focus on companies approaching key clinical trial catalysts — where rigorous analysis and predictive modelling can create asymmetric outcomes.

Our proprietary AI model incorporates Opyl’s TrialKey platform — an engine trained on over 450,000 historical clinical trials to estimate the probability of success — and integrates traditional company and macro fundamentals to identify high-probability, high-impact events. These insights are complemented by deep fundamental research into mechanism of action, competitive landscape, and risk-reward profile, enabling conviction-weighted investment decisions.

Designed for wholesale investors, the fund offers a disciplined strategy grounded in predictive analytics, active portfolio management, and rigorous due diligence — transforming complexity into opportunity.

AI Biotech Fund

Org chart

Teams

Offices